MediSix closes RM78.4m financing for life-saving cancer therapies
Kuala Lumpur: MediSix Therapeutics Pte Ltd, a development-stage cell therapy company announced the close of financing totalling US$ 20 million (RM 78.4 million) led by Lightstone Ventures and participation of Temasek and Osage University Partners.
"This financing is a testament to MediSix' novel approach to developing treatments that target T-cell malignancies and investors' confidence in our ability to quickly bring these potentially life-saving therapies to patients affected with these aggressive forms of cancer," said MediSix Therapeutics founder, Dario Campana.
The financing will be used to build out the team, advance product development, and initiate early pre-clinical studies as MediSix is taking a novel approach to engineer chimeric antigen receptor ("CAR") T-cells to target T-cell leukemia and lymphoma.
MediSix also announced appointment of Chief Scientific officer, Murray Robinson, PhD who has more than 25 years of experience in drug discovery, development and translational medicine in the field of oncology, a statement said.
"Lightstone Ventures, Temasek, and Osage University Partners are pleased to support MediSix as it advances its pre-clinical development programme and excited to have Dr. Robinson joining the team," said Chief Executive Officer of Lightstone Singapore Pte Ltd, Kenneth D. Noonan.
MediSix has an exclusive licensing agreement with the National University of Singapore (NUS) to develop breakthrough treatments for T-cell blood cancers and also rights to an underlying cell engineering platform, enabling applications beyond T-cell malignancies. –Bernama